A new standard for Parkinson’s care.

Cost-effective clinical biomarkers for Parkinson’s disease.

Parkinson’s disease care poses several challenges:

  • Treatment adjustments get harder with disease progression.
  • Reliable, quantitative symptom estimation is seldom used.
  • Quality of care can differ between hospitals and regions.
  • Parkinson’s cases are expected to rise with an ageing population.

As a result, Parkinson’s disease treatment seldom reaches its true potential. And the cost of PD treatment and care is high and rising.

Our ANLIVA™ platform will provide cost-effective assistance, based on automatic clinical biomarkers for Parkinson’s disease-related symptoms.

ANLIVA will be labeled SaMD (Software-as-a-Medical-Device) in regulatory terms: Software intended for one or more medical purposes that perform these purposes without being part of a hardware medical device.

The ANLIVA digital health platform has the potential to sharply reduce costs for society and improve the quality of life for over 10 million people around the world with Parkinson’s disease.

Preliminary positive results for our symptom quantification allow us to develop new partnerships for AI-assisted optimization of Deep brain stimulation (DBS) and other late-stage Parkinson’s disease treatments.

Our vision is that ANLIVA will become a new standard for objective, equal, globally accessible, and cost-effective Parkinson’s care.

Stay up-to-date

Sign up to receive updates on our latest developments.

    For information on how we process your data and protect your privacy, read our Privacy Policy.

    The birth of a global platform for neurological diseases.

    Initial pilot studies of our core components show encouraging results in achieving accurate tremor estimations. These and other results inspire us to make the ANLIVA platform globally available for Parkinson’s disease patients.

    There is already great market interest, and we have attracted a number of European clinics for upcoming clinical trials. In addition to Parkinson’s disease, there are strong indications that our core technology can support the treatment of Alzheimer’s disease, ALS, MS, and other neurological diseases.

    Data collected using ANLIVA can also provide a new valuable source for insights into Parkinson’s disease. This opens opportunities for caregivers and life science companies to develop new Parkinson’s disease treatments.

    Market launch in 2023.

    Our proprietary mathematical models are developed under Professor Alexander Medvedev at Uppsala University, supported with ~$1M funding from the Swedish innovation agency Vinnova.

    Stardots has raised expansion capital with VNV Global AB as a leading investor with ~$2M to prepare for market launch. Other investors in Stardots include Uppsala University Invest AB and Stockholm University Holding AB.

    The ANLIVA platform is to be CE- and FDA approved and ready for launch in EU/U.S. late 2023.